Insulin amyloidosis reduces the stability and activity of pharmaceutical compositions of insulin preparations and its analogues, aggravates the course of diabetes mellitus, increases the cost of the treatment procedure and makes it less accessible [92]. Here, INS is linked to diabetes mellitus.